GENMAB AS DK0010272202

Verkoopcijfers Darzalex halfjaar 2018

1. Kaviaar 18 juli 2018 17:41

   auteur info

   • Kaviaar

     Lid sinds: 22 jan 2013

     Laatste bezoek: 22 apr 2024

   • Aanbevelingen

     Ontvangen: 5254

     Gegeven: 3466

   •    Aantal posts: 13.868

   Company Announcement
   •Net sales of DARZALEX in the second quarter of 2018 totaled USD 511 million
   •Genmab will receive royalties on worldwide net sales from Janssen Biotech, Inc.
   
   Copenhagen, Denmark; July 17, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 511 million in the second quarter of 2018. Net sales were USD 298 million in the U.S. and USD 213 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
   
   About DARZALEX®(daratumumab)
   DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.6 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for treatment of adults with relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market. For more information, visit www.DARZALEX.com.
   
   Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5
   
   Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and frontline multiple myeloma settings and in amyloidosis. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases, such as NKT-cell lymphoma, myelodysplastic syndromes, B and T-ALL. Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.
   
   ir.genmab.com/news-releases/news-rele...
   
   May 8, 2018; Copenhagen, Denmark;
   Interim Report for the First Quarter of 2018
   
   Highlights
   •USD 432 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 310 million
   
   ir.genmab.com/news-releases/news-rele...